Premium
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
Author(s) -
Levy J. H.,
Moore K. T.,
Neal M. D.,
Schneider D.,
Marcsisin V. S.,
Ariyawansa J.,
Weitz J. I.
Publication year - 2018
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.13894
Subject(s) - rivaroxaban , tranexamic acid , medicine , prothrombin complex concentrate , saline , anesthesia , prothrombin time , pharmacology , surgery , warfarin , blood loss , atrial fibrillation
Essentials Specific reversal agents for managing severe factor Xa inhibitor‐associated bleeding are lacking. We assessed 4‐factor‐prothrombin complex concentrate (4F‐PCC) and tranexamic acid (TXA). 4F‐PCC, but not TXA, reduced the prothrombin time and increased endogenous thrombin potential. These agents may be viable options for reversal of therapeutic doses of rivaroxaban.Summary Background Oral activated factor X inhibitors such as rivaroxaban are widely used, but specific reversal agents are lacking. Although four‐factor prothrombin complex concentrate (4F‐ PCC ) and tranexamic acid ( TXA ) are sometimes used to manage serious bleeding, their efficacy is unknown. Prior studies in healthy subjects taking rivaroxaban revealed that 4F‐ PCC partially reverses the prolonged prothrombin time ( PT ), and fully restores the endogenous thrombin potential ( ETP ). The effect of TXA has not been evaluated. Methods In this double‐blind, parallel‐group study, 147 healthy volunteers given rivaroxaban 20 mg twice daily for 3 days were randomized after their morning dose on day 4 to receive intravenous 4F‐ PCC (50 IU kg −1 ), TXA (1.0 g), or saline. Standardized punch biopsies were performed at baseline and after 4F‐ PCC , TXA or saline administration. Reversal was assessed by measuring bleeding duration and bleeding volume at biopsy sites, and by determining the PT and ETP . Results As compared with saline, 4F‐ PCC partially reversed the PT and completely reversed the ETP , whereas TXA had no effect. Neither 4F‐ PCC nor TXA reduced bleeding duration or volume. All treatments were well tolerated, with no recorded adverse events. Conclusions Although 4F‐ PCC reduced the PT and increased the ETP in volunteers given supratherapeutic doses of rivaroxaban, neither 4F‐ PCC nor TXA influenced punch biopsy bleeding.